ClinicalTrials.gg
DrugBiological

Hyaluronidase (human recombinant) clinical trials

Also written Hylenex, rHuPH20 and Chemophase.

studies test it
69
open now
10
in phase 3
20
first study started
2005

How each study uses hyaluronidase (human recombinant) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the hyaluronidase (human recombinant) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Dec 2005 · HYLENEX RECOMBINANT · BLA 021859 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

PH20
8
recombinant human hyaluronidase
6
Recombinant human hyaluronidase PH20 (rHuPH20)
5
Recombinant human hyaluronidase PH20
4
PEGylated Recombinant Human Hyaluronidase (PEGPH20)
3

Brand

Hylenex
20
Chemophase
3

Development codes

rHuPH20
16

In one entry with another drug

Given together, or one or the other

Efgartigimod PH20 SC
22
ARGX-113 PH20 SC
2
Daratumumab/rHuPH20
2
CINRYZE with rHuPH20
2

Studies by the year they started

69 studies that test it; most in 2024 (7)

Studies that test hyaluronidase (human recombinant), by start year
YearStudies
20051
20063
20072
20086
20096
20105
20114
20121
20133
20152
20162
20172
20181
20192
20204
20215
20222
20234
20247
20252
20265

Who runs them

Industry 59 · Other 10

argenx (22) · Halozyme Therapeutics (20) · Baxalta now part of Shire (3) · Baxter Healthcare Corporation (3) · ViiV Healthcare (2) · Shire (2) · SWOG Cancer Research Network (1) · Bristol-Myers Squibb (1)

Often tested with

Tested in the same studies.

Efgartigimod alfa (22) · Insulin Lispro (5) · Daratumumab (4) · Lenalidomide (2) · C1 esterase inhibitor (human) (2) · Insulin, Regular, Human (2) · Pomalidomide (2) · Dexamethasone (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 3 in phase 3

Studies that test hyaluronidase (human recombinant), phase 3 first.

Studies

Open first, then newest update. How each study uses hyaluronidase (human recombinant) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 69

See all 69 studies that test hyaluronidase (human recombinant) →

Given beside what is tested · 25 — hyaluronidase (human recombinant) is usual care or a partner of the new treatment

Showing 20 of 25.

Codes

What other systems call hyaluronidase (human recombinant) · ClinicalTrials.gg INT015395

  • UNII (FDA) 743QUY4VD8HYALURONIDASE (HUMAN RECOMBINANT)Confirmed FDA, Wikidata
  • RxNorm 1300478One source FDA
  • Wikidata Q904015hyaluronidaseConfirmed FDA, Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.